Merck: successful phase 3 trial in breast cancer
(CercleFinance.com) - Merck announced on Tuesday that a phase 3 clinical trial evaluating the efficacy of patritumab deruxtecan in non-small cell lung cancer has met its primary endpoint.
The trial involved patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who had previously received treatment with tyrosine kinase inhibitors (TKIs).
Merck says that patritumab deruxtecan showed a 'statistically significant' improvement in patients' progression-free survival compared to chemotherapy.
The US pharma group points out that data on patients' overall survival, the study's secondary endpoint, were not sufficiently refined to be reported.
Patritumab deruxtecan, an antibody-drug conjugate discovered by Japan's Daiichi Sankyo, is in joint clinical development with Merck.
Non-small-cell lung cancer accounts for almost 85% of bronchial cancer cases worldwide, 70% of which are diagnosed at an advanced stage.
EGFR mutations occur in 14% to 38% of non-small-cell lung cancers.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The trial involved patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who had previously received treatment with tyrosine kinase inhibitors (TKIs).
Merck says that patritumab deruxtecan showed a 'statistically significant' improvement in patients' progression-free survival compared to chemotherapy.
The US pharma group points out that data on patients' overall survival, the study's secondary endpoint, were not sufficiently refined to be reported.
Patritumab deruxtecan, an antibody-drug conjugate discovered by Japan's Daiichi Sankyo, is in joint clinical development with Merck.
Non-small-cell lung cancer accounts for almost 85% of bronchial cancer cases worldwide, 70% of which are diagnosed at an advanced stage.
EGFR mutations occur in 14% to 38% of non-small-cell lung cancers.
Copyright (c) 2024 CercleFinance.com. All rights reserved.